Molecular and biologic analysis of histone deacetylase inhibitors with diverse specificities.

Mol Cancer Ther 2013 Dec 3;12(12):2709-21. Epub 2013 Oct 3.

Corresponding Author: Ricky Johnstone, Peter MacCallum Cancer Centre, St Andrews Place, East Melbourne, Victoria 3002, Australia.

Histone deacetylase inhibitors (HDACi) are anticancer agents that induce hyperacetylation of histones, resulting in chromatin remodeling and transcriptional changes. In addition, nonhistone proteins, such as the chaperone protein Hsp90, are functionally regulated through hyperacetylation mediated by HDACis. Histone acetylation is thought to be primarily regulated by HDACs 1, 2, and 3, whereas the acetylation of Hsp90 has been proposed to be specifically regulated through HDAC6. We compared the molecular and biologic effects induced by an HDACi with broad HDAC specificity (vorinostat) with agents that predominantly inhibited selected class I HDACs (MRLB-223 and romidepsin). MRLB-223, a potent inhibitor of HDACs 1 and 2, killed tumor cells using the same apoptotic pathways as the HDAC 1, 2, 3, 6, and 8 inhibitor vorinostat. However, vorinostat induced histone hyperacetylation and killed tumor cells more rapidly than MRLB-223 and had greater therapeutic efficacy in vivo. FDCP-1 cells dependent on the Hsp90 client protein Bcr-Abl for survival, were killed by all HDACis tested, concomitant with caspase-dependent degradation of Bcr-Abl. These studies provide evidence that inhibition of HDAC6 and degradation of Bcr-Abl following hyperacetylation of Hsp90 is likely not a major mechanism of action of HDACis as had been previously posited.

Download full-text PDF

Source
http://mct.aacrjournals.org/content/early/2013/11/22/1535-71
Web Search
http://mct.aacrjournals.org/cgi/doi/10.1158/1535-7163.MCT-13
Publisher Site
http://dx.doi.org/10.1158/1535-7163.MCT-13-0626DOI Listing
December 2013
38 Reads

Publication Analysis

Top Keywords

deacetylase inhibitors
8
tumor cells
8
degradation bcr-abl
8
histone deacetylase
8
killed tumor
8
molecular biologic
8
agents inhibited
4
inhibited selected
4
vorinostat agents
4
concomitant caspase-dependent
4
specificity vorinostat
4
hdac specificity
4
selected class
4
tested concomitant
4
mrlb-223 potent
4
romidepsin mrlb-223
4
mrlb-223 romidepsin
4
class hdacs
4
hdacs mrlb-223
4
caspase-dependent degradation
4

Similar Publications